208 related articles for article (PubMed ID: 22562956)
1. Repression of malignant tumor progression upon pharmacologic IGF1R blockade in a mouse model of insulinoma.
Zumsteg A; Caviezel C; Pisarsky L; Strittmatter K; García-Echeverría C; Hofmann F; Christofori G
Mol Cancer Res; 2012 Jun; 10(6):800-9. PubMed ID: 22562956
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
Tanno B; Mancini C; Vitali R; Mancuso M; McDowell HP; Dominici C; Raschellà G
Clin Cancer Res; 2006 Nov; 12(22):6772-80. PubMed ID: 17121898
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis.
Moser C; Schachtschneider P; Lang SA; Gaumann A; Mori A; Zimmermann J; Schlitt HJ; Geissler EK; Stoeltzing O
Eur J Cancer; 2008 Jul; 44(11):1577-86. PubMed ID: 18445520
[TBL] [Abstract][Full Text] [Related]
4. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells.
Höpfner M; Huether A; Sutter AP; Baradari V; Schuppan D; Scherübl H
Biochem Pharmacol; 2006 May; 71(10):1435-48. PubMed ID: 16530734
[TBL] [Abstract][Full Text] [Related]
5. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
Maiso P; Ocio EM; Garayoa M; Montero JC; Hofmann F; García-Echeverría C; Zimmermann J; Pandiella A; San Miguel JF
Br J Haematol; 2008 May; 141(4):470-82. PubMed ID: 18341634
[TBL] [Abstract][Full Text] [Related]
6. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours.
Höpfner M; Baradari V; Huether A; Schöfl C; Scherübl H
Endocr Relat Cancer; 2006 Mar; 13(1):135-49. PubMed ID: 16601284
[TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of matrilysin.
Adachi Y; Li R; Yamamoto H; Min Y; Piao W; Wang Y; Imsumran A; Li H; Arimura Y; Lee CT; Imai K; Carbone DP; Shinomura Y
Carcinogenesis; 2009 Aug; 30(8):1305-13. PubMed ID: 19493905
[TBL] [Abstract][Full Text] [Related]
8. The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion.
Tazzari PL; Tabellini G; Bortul R; Papa V; Evangelisti C; Grafone T; Martinelli G; McCubrey JA; Martelli AM
Leukemia; 2007 May; 21(5):886-96. PubMed ID: 17361225
[TBL] [Abstract][Full Text] [Related]
9. The IGFR1 inhibitor NVP-AEW541 disrupts a pro-survival and pro-angiogenic IGF-STAT3-HIF1 pathway in human glioblastoma cells.
Gariboldi MB; Ravizza R; Monti E
Biochem Pharmacol; 2010 Aug; 80(4):455-62. PubMed ID: 20488164
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.
Scotlandi K; Manara MC; Nicoletti G; Lollini PL; Lukas S; Benini S; Croci S; Perdichizzi S; Zambelli D; Serra M; García-Echeverría C; Hofmann F; Picci P
Cancer Res; 2005 May; 65(9):3868-76. PubMed ID: 15867386
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas.
Piao W; Wang Y; Adachi Y; Yamamoto H; Li R; Imsumran A; Li H; Maehata T; Ii M; Arimura Y; Lee CT; Shinomura Y; Carbone DP; Imai K
Mol Cancer Ther; 2008 Jun; 7(6):1483-93. PubMed ID: 18566219
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer.
Gotlieb WH; Bruchim I; Gu J; Shi Y; Camirand A; Blouin MJ; Zhao Y; Pollak MN
Gynecol Oncol; 2006 Feb; 100(2):389-96. PubMed ID: 16300820
[TBL] [Abstract][Full Text] [Related]
13. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H
Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma.
Friedrichs N; Küchler J; Endl E; Koch A; Czerwitzki J; Wurst P; Metzger D; Schulte JH; Holst MI; Heukamp LC; Larsson O; Tanaka S; Kawai A; Wardelmann E; Buettner R; Pietsch T; Hartmann W
J Pathol; 2008 Dec; 216(4):428-39. PubMed ID: 18855347
[TBL] [Abstract][Full Text] [Related]
15. Insulin-like growth factor-I receptor inhibition by specific tyrosine kinase inhibitor NVP-AEW541 in endometrioid and serous papillary endometrial cancer cell lines.
Attias-Geva Z; Bentov I; Fishman A; Werner H; Bruchim I
Gynecol Oncol; 2011 May; 121(2):383-9. PubMed ID: 21295335
[TBL] [Abstract][Full Text] [Related]
16. Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma.
Abraham J; Prajapati SI; Nishijo K; Schaffer BS; Taniguchi E; Kilcoyne A; McCleish AT; Nelon LD; Giles FG; Efstratiadis A; LeGallo RD; Nowak BM; Rubin BP; Malempati S; Keller C
Mol Cancer Ther; 2011 Apr; 10(4):697-707. PubMed ID: 21447712
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.
Browne BC; Eustace AJ; Kennedy S; O'Brien NA; Pedersen K; McDermott MS; Larkin A; Ballot J; Mahgoub T; Sclafani F; Madden S; Kennedy J; Duffy MJ; Crown J; O'Donovan N
Breast Cancer Res Treat; 2012 Dec; 136(3):717-27. PubMed ID: 23117852
[TBL] [Abstract][Full Text] [Related]
18. Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001.
Baumann P; Hagemeier H; Mandl-Weber S; Franke D; Schmidmaier R
Anticancer Drugs; 2009 Apr; 20(4):259-66. PubMed ID: 19240643
[TBL] [Abstract][Full Text] [Related]
19. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
Warshamana-Greene GS; Litz J; Buchdunger E; García-Echeverría C; Hofmann F; Krystal GW
Clin Cancer Res; 2005 Feb; 11(4):1563-71. PubMed ID: 15746061
[TBL] [Abstract][Full Text] [Related]
20. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
